Rockwell's iron replacement drug Triferic under FDA review
This article was originally published in Scrip
Executive Summary
Shares of Rockwell Medical shot up almost 10% in morning trading on 28 May after the company revealed the FDA had accepted for review the new drug application (NDA) for Triferic (soluble ferric pyrophosphate citrate), an investigational iron replacement therapy.